Fumagillin has been intensely studied due to its potential in the treatment of amebiasis [54], microsporidiosis [55] and most recently, for its anti-angiogenic activity as inhibitor of the human type 2 methionine aminopeptidase (MetAP2) [56,57]. This evidence concerns the gene METAP2 and microsporidiosis.